Frontiers in Cardiovascular Medicine (Feb 2023)

Utility of atherosclerosis-associated serum antibodies against colony-stimulating factor 2 in predicting the onset of acute ischemic stroke and prognosis of colorectal cancer

  • Shu-Yang Li,
  • Shu-Yang Li,
  • Yoichi Yoshida,
  • Yoichi Yoshida,
  • Masaaki Kubota,
  • Masaaki Kubota,
  • Bo-Shi Zhang,
  • Tomoo Matsutani,
  • Masaaki Ito,
  • Satoshi Yajima,
  • Kimihiko Yoshida,
  • Seiichiro Mine,
  • Seiichiro Mine,
  • Seiichiro Mine,
  • Toshio Machida,
  • Toshio Machida,
  • Toshio Machida,
  • Aiko Hayashi,
  • Minoru Takemoto,
  • Minoru Takemoto,
  • Koutaro Yokote,
  • Mikiko Ohno,
  • Mikiko Ohno,
  • Eiichiro Nishi,
  • Eiichiro Nishi,
  • Kenichiro Kitamura,
  • Ikuo Kamitsukasa,
  • Hirotaka Takizawa,
  • Mizuki Sata,
  • Mizuki Sata,
  • Kazumasa Yamagishi,
  • Hiroyasu Iso,
  • Norie Sawada,
  • Shoichiro Tsugane,
  • Katsuro Iwase,
  • Hideaki Shimada,
  • Hideaki Shimada,
  • Yasuo Iwadate,
  • Yasuo Iwadate,
  • Takaki Hiwasa,
  • Takaki Hiwasa,
  • Takaki Hiwasa,
  • Takaki Hiwasa

DOI
https://doi.org/10.3389/fcvm.2023.1042272
Journal volume & issue
Vol. 10

Abstract

Read online

IntroductionAutoantibodies against inflammatory cytokines may be used for the prevention of atherosclerosis. Preclinical studies consider colony-stimulating factor 2 (CSF2) as an essential cytokine with a causal relationship to atherosclerosis and cancer. We examined the serum anti-CSF2 antibody levels in patients with atherosclerosis or solid cancer.MethodsWe measured the serum anti-CSF2 antibody levels via amplified luminescent proximity homogeneous assay-linked immunosorbent assay based on the recognition of recombinant glutathione S-transferase-fused CSF2 protein or a CSF2-derived peptide as the antigen.ResultsThe serum anti-CSF2 antibody (s-CSF2-Ab) levels were significantly higher in patients with acute ischemic stroke (AIS), acute myocardial infarction (AMI), diabetes mellitus (DM), and chronic kidney disease (CKD) compared with healthy donors (HDs). In addition, the s-CSF2-Ab levels were associated with intima-media thickness and hypertension. The analyzes of samples obtained from a Japan Public Health Center-based prospective study suggested the utility of s-CSF2-Ab as a risk factor for AIS. Furthermore, the s-CSF2-Ab levels were higher in patients with esophageal, colorectal, gastric, and lung cancer than in HDs but not in those with mammary cancer. In addition, the s-CSF2-Ab levels were associated with unfavorable postoperative prognosis in colorectal cancer (CRC). In CRC, the s-CSF2-Ab levels were more closely associated with poor prognosis in patients with p53-Ab-negative CRC despite the lack of significant association of the anti-p53 antibody (p53-Ab) levels with the overall survival.ConclusionS-CSF2-Ab was useful for the diagnosis of atherosclerosis-related AIS, AMI, DM, and CKD and could discriminate poor prognosis, especially in p53-Ab-negative CRC.

Keywords